Amgen [AMGN] vs Johnson & Johnson [JNJ] Detailed Stock Comparison
Amgen
NASDAQ
Loading...
Johnson & Johnson
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Amgen wins in 6 metrics, Johnson & Johnson wins in 14 metrics, with 0 ties. Johnson & Johnson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Amgen | Johnson & Johnson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 27.04 | 17.92 | Johnson & Johnson |
| Price-to-Book Ratio | 25.72 | 5.13 | Johnson & Johnson |
| Debt-to-Equity Ratio | 924.46 | 64.69 | Johnson & Johnson |
| PEG Ratio | 14.36 | 15.79 | Amgen |
| EV/EBITDA | 13.24 | 14.37 | Amgen |
| Profit Margin (TTM) | 17.39% | 25.00% | Johnson & Johnson |
| Operating Margin (TTM) | 28.73% | 28.91% | Johnson & Johnson |
| EBITDA Margin (TTM) | 28.73% | 28.91% | Johnson & Johnson |
| Return on Equity | 105.67% | 30.21% | Amgen |
| Return on Assets (TTM) | 7.04% | 7.61% | Johnson & Johnson |
| Free Cash Flow (TTM) | $10.39B | $18.06B | Johnson & Johnson |
| Dividend Yield | 3.20% | 2.47% | Amgen |
| 1-Year Return | -11.11% | 1.94% | Johnson & Johnson |
| Price-to-Sales Ratio (TTM) | 4.68 | 4.45 | Johnson & Johnson |
| Enterprise Value | $208.21B | $434.87B | Johnson & Johnson |
| EV/Revenue Ratio | 6.10 | 4.80 | Johnson & Johnson |
| Gross Profit Margin (TTM) | 63.58% | 67.87% | Johnson & Johnson |
| Revenue per Share (TTM) | $63 | $38 | Amgen |
| Earnings per Share (Diluted) | $10.98 | $9.34 | Amgen |
| Beta (Stock Volatility) | 0.48 | 0.40 | Johnson & Johnson |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Amgen vs Johnson & Johnson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Amgen | 0.60% | -3.16% | 2.19% | 4.62% | 2.77% | 14.50% |
| Johnson & Johnson | 1.57% | -0.58% | 7.32% | 8.33% | 10.18% | 16.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Amgen | -11.11% | 20.56% | 23.35% | 72.29% | 430.71% | 262.54% |
| Johnson & Johnson | 1.94% | -2.21% | 12.60% | 69.28% | 179.07% | 163.35% |
Performance & Financial Health Analysis: Amgen vs Johnson & Johnson
| Metric | AMGN | JNJ |
|---|---|---|
| Market Information | ||
| Market Cap | $159.63B | $402.99B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 1,887,960 | 8,288,260 |
| 90 Day Avg. Volume | 2,390,963 | 8,981,913 |
| Last Close | $296.88 | $167.33 |
| 52 Week Range | $253.30 - $340.89 | $140.68 - $169.99 |
| % from 52W High | -12.91% | -1.56% |
| All-Time High | $346.85 (Jul 22, 2024) | $186.69 (Apr 25, 2022) |
| % from All-Time High | -14.41% | -10.37% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.06% |
| Quarterly Earnings Growth | 0.09% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.17% | 0.25% |
| Operating Margin (TTM) | 0.29% | 0.29% |
| Return on Equity (TTM) | 1.06% | 0.30% |
| Debt to Equity (MRQ) | 924.46 | 64.69 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $11.54 | $32.61 |
| Cash per Share (MRQ) | $16.38 | $7.84 |
| Operating Cash Flow (TTM) | $12.19B | $23.03B |
| Levered Free Cash Flow (TTM) | $13.09B | $11.08B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.20% | 2.47% |
| Last 12-Month Dividend | $9.26 | $3.72 |
Valuation & Enterprise Metrics Analysis: Amgen vs Johnson & Johnson
| Metric | AMGN | JNJ |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 27.04 | 17.92 |
| Forward P/E | 14.36 | 15.79 |
| PEG Ratio | 14.36 | 15.79 |
| Price to Sales (TTM) | 4.68 | 4.45 |
| Price to Book (MRQ) | 25.72 | 5.13 |
| Market Capitalization | ||
| Market Capitalization | $159.63B | $402.99B |
| Enterprise Value | $208.21B | $434.87B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.10 | 4.80 |
| Enterprise to EBITDA | 13.24 | 14.37 |
| Risk & Other Metrics | ||
| Beta | 0.48 | 0.40 |
| Book Value per Share (MRQ) | $11.54 | $32.61 |
Financial Statements Comparison: Amgen vs Johnson & Johnson
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AMGN | JNJ |
|---|---|---|
| Revenue/Sales | $8.15B | $21.89B |
| Cost of Goods Sold | $2.97B | $7.36B |
| Gross Profit | $5.18B | $14.54B |
| Research & Development | $1.49B | $3.23B |
| Operating Income (EBIT) | $1.18B | $6.30B |
| EBITDA | $4.08B | $8.72B |
| Pre-Tax Income | $1.97B | $13.63B |
| Income Tax | $243.00M | $2.63B |
| Net Income (Profit) | $1.73B | $11.00B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AMGN | JNJ |
|---|---|---|
| Cash & Equivalents | $8.81B | $38.47B |
| Total Current Assets | $26.93B | $71.55B |
| Total Current Liabilities | $23.01B | $56.90B |
| Long-Term Debt | $54.01B | $38.36B |
| Total Shareholders Equity | $6.21B | $78.11B |
| Retained Earnings | $-27.14B | N/A |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AMGN | JNJ |
|---|---|---|
| Operating Cash Flow | $1.71B | $6.35B |
| Capital Expenditures | $-411.00M | $-795.00M |
| Free Cash Flow | $980.00M | $3.37B |
| Debt Repayment | $-2.50B | $-2.87B |
| Common Stock Repurchase | N/A | $-2.13B |
Short Interest & Institutional Ownership Analysis
| Metric | AMGN | JNJ |
|---|---|---|
| Shares Short | 14.70M | 18.27M |
| Short Ratio | 5.46 | 2.21 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 1,887,960 | 8,288,260 |
| Average Daily Volume (90 Day) | 2,390,963 | 8,981,913 |
| Shares Outstanding | 537.00M | 2.41B |
| Float Shares | 536.32M | 2.40B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.84% | 0.74% |
Dividend Analysis & Yield Comparison: Amgen vs Johnson & Johnson
| Metric | AMGN | JNJ |
|---|---|---|
| Last 12-Month Dividend | $9.26 | $3.72 |
| Last 12-Month Dividend Yield | 3.20% | 2.47% |
| 3-Year Avg Annual Dividend | $8.72 | $3.97 |
| 3-Year Avg Dividend Yield | 0.79% | 0.75% |
| 3-Year Total Dividends | $26.16 | $11.92 |
| Ex-Dividend Date | May 16, 2025 | Feb 18, 2025 |